AANEM Endorsement of the 2023 ACC Expert Consensus Decision Pathway for Cardiac Amyloidosis

AANEM has recently endorsed the 2023 American College of Cardiology (ACC) Expert Consensus Decision Pathway for Cardiac Amyloidosis which became available online Monday, January 23, 2023 with the print copy published in the JACC print issue on March 21.
 

Cardiac amyloidosis is a rare disease which occurs when there is a buildup of amyloid fibrils (an abnormal protein) in the heart tissue; if left untreated, cardiac amyloidosis can cause heart failure. This document focuses on the need for a multidisciplinary approach to individual care. Dedicated experts across diverse medical specialties are vastly important to address and optimize the full range of care levels. Individuals with cardiac amyloidosis often have extracardiac manifestations involving the kidney, nervous system, gastrointestinal tract and musculoskeletal systems that can lead to significant morbidity and impairment to quality of life.
 

This document was endorsed by the American Association of Neuromuscular & Electrodiagnostic Medicine, the Heart Failure Society of America and the International Society of Amyloidosis. The American Academy of Neurology affirms the value of the statement.

Please click here to read the 2023 ACC Expert Consensus Decision Pathway for Cardiac Amyloidosis.